Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma

Table 3 Survival Analysis for patients with OEC.

Variables	Case number	PFS						OS
		Unadjusted			Adjusted*			Unadjusted			Adjusted*
		HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
IGFBP-3
High	36	1.00	1.36-7.77	0.01	1.00	0.27-2.27	0.65	1.00	1.28-9.38	0.01	1.00	0.27-2.85	0.82
Low	24	3.25			0.78			3.46			0.87
P53
Normal	39	1.00	0.43-2.42	0.97	1.00	0.53-3.74	0.49	1.00	0.29-2.02	0.60	1.00	0.24-2.32	0.62
Overexpression	21	1.01			1.41			0.77			0.75
Methylation
≤ 3%	20	1.00	0.76-5.82	0.14	1.00	0.20-2.033	0.45	1.00	0.91-9.60	0.07	1.00	0.16-2.45	0.49
> 3%	20	2.11			0.64			2.95			0.62
IGFBP-3 expression and *IGFBP-3* methylation
High IGFBP-3 Methylation ≤ 3%	18	1.00			1.00			1.00			1.00
Unparallel	10	2.38	0.53-10.64	0.26	1.46	0.09-2.49	0.37	3.16	0.53-19.01	0.21	0.56	0.08-3.78	0.56
Low IGFBP-3 Methylation > 3%	12	4.45	1.17-16.85	0.03	0.37	0.07-1.88	0.23	7.18	1.48-34.89	0.02	0.64	0.11-3.68	0.62
IGFBP-3 expression and *IGFBP-3* methylation with normal p53
High IGFBP-3 Methylation ≤ 3%	10	1.00			1.00			1.00			1.00
Unparallel	6	4.67	0.58-37.40	0.15	0.47	0.03-7.09	0.56	4.81	0.57-40.40	0.15	0.37	0.18-7.68	0.52
Low IGFBP-3 Methylation > 3%	8	21.47	2.57-179.19	0.005	0.40	0.07-28.05	0.82	20.38	2.39-173.89	0.006	0.79	0.27-23.40	0.89

PFS indicates progression-free survival; OS indicates overall survival; HR indicates hazard ratio; 95% CI confidence interval; IGFBP-3, insulin-like growth factor binding protein-3; Unparallel indicates either high IGFBP-3 and IGFBP-3 promoter methylation > 3% or low IGFBP-3 and IGFBP-3 promoter methylation ≤ 3%.
*Adjusted by age at diagnosis, disease stage and histological grade.

ISSN: 1476-4598